Home > Insider Trading > Filing (0001562180-23-003481)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1678660	Prelude Therapeutics Inc	PRLD	Pharmaceutical Preparations (2834)	811384762

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1683913	Jane Huang	C/O Prelude Therapeutics Incorporated 200 Powder Mill Road Wilmington DE 19801	President, Cmo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-04-04	37,500	$0.00	37,500	No	4	M	Direct
Common Stock	Disposition	2023-04-06	13,280	$6.12	24,220	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2023-04-04	37,500	$0.00	37,500	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
112,500			No	4	M	Direct

Footnotes

Each Restricted Stock Unit ("RSUs") represents a contingent right to receive one share of Issuer's Common Stock.
Represents the aggregate number of shares sold by the reporting person as a result of a mandatory sale to cover taxes and fees due upon the release and settlement of the RSUs. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.